Economic Evaluation of Specific Immunotherapy Versus Symptomatic Treatment of Allergic Rhinitis in Germany

Schädlich, Peter K.; Brecht, Josef Georg

doi:10.2165/00019053-200017010-00003

Cited by 71 publications

(34 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The economic evaluation of specific immunotherapy vs symptomatic treatment of allergic rhinitis was modelized in Germany and France (1146,1680) and it was found to be cost effective due to the long-term effects of immunotherapy.…”

Section: Safetymentioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,867

1,761

View full text Add to dashboard Cite

Section: Safetymentioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,867

1,761

View full text Add to dashboard Cite

“…Several health economics studies that include cost-effectiveness and cost-utility calculations have demonstrated that SCIT and SLIT are economically advantageous to pharmacotherapy. [209][210][211][212] Seven studies based on RCT data conducted from a health system perspective and using QALYS as their outcome measure suggests that SLIT and SCIT would be considered cost-effective in this patient population in United Kingdom at the standard National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold of £20 000 (€24 616) per QALY. [213][214][215][216][217][218][219] The studies comparing SCIT and SLIT have given mixed results and do not allow us to conclude whether either treatment is more cost-effective.…”

Section: Pharmacoeconomic Aspe Cts Of Ait Versus Pharmacothe Rapy Fmentioning

confidence: 99%

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Roberts

Pfaar

Akdiş

et al. 2017

Allergy

594

705

View full text Add to dashboard Cite

drawn on data from a systematic review of the literature, more recent published studies and multistakeholder expert clinical opinion. This Guideline is aimed at healthcare professionals who are encouraged to take the recommendations into account in the context of delivering clinical care. This Guideline is not a substitute for professional clinical judgment, which professionals need to exercise in the context of delivering personalised healthcare. AbstractAllergic rhinoconjunctivitis (AR) is an allergic disorder of the nose and eyes affecting about a fifth of the general population. Symptoms of AR can be controlled with allergen avoidance measures and pharmacotherapy. However, many patients continue to have ongoing symptoms and an impaired quality of life; pharmacotherapy may also induce some side-effects. Allergen immunotherapy (AIT) represents the only currently available treatment that targets the underlying pathophysiology, and it may have a disease-modifying effect. Either the subcutaneous (SCIT) or sublingual (SLIT) routes may be used. This Guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on AIT for AR and is part of the EAACI presidential project "EAACI Guidelines on Allergen Immunotherapy." It aims to provide evidence-based clinical recommendations and has been informed by a formal systematic review and meta-analysis. Its generation has followed the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach.The process included involvement of the full range of stakeholders. In general, broad evidence for the clinical efficacy of AIT for AR exists but a product-specific evaluation of evidence is recommended. In general, SCIT and SLIT are recommended for both seasonal and perennial AR for its short-term benefit. The strongest evidence for long-term benefit is documented for grass AIT (especially for the grass 766 | ROBERTS, PFAAR ET AL. tablets) where long-term benefit is seen. To achieve long-term efficacy, it is recommended that a minimum of 3 years of therapy is used. Many gaps in the evidence base exist, particularly around long-term benefit and use in children. | ME TH ODOLOGYThis Guideline was produced using the Appraisal of Guidelines forResearch & Evaluation (AGREE II) approach, 17,18 a structured approach to guideline production (see Table S1). This is designed to ensure appropriate representation of the full range of stakeholders, a careful search for and critical appraisal of the relevant literature, a systematic approach to the formulation and presentation of recommendations and steps to ensure that the risk of bias is minimized at each step of the process. The process started on April 2015 beginning with detailed face-to-face discussions agreeing on the process and the key clinical areas to address, followed by face-to-face meetings, and regular web conferences in which professional and lay representatives participated. | Clarifying the scope and purpose of the guidelinesThe scope of this EAACI Guideline is multifaceted...

show abstract

“…Pharmacoeconomic models based on data provided by clinical trials and meta-analyses indicate that SIT is cost-efficient (146). One of the few real patient cohort studies to investigate cost-effectiveness of SCIT was performed in US children with allergic rhinitis; patients in the SCIT group incurred 33% lower healthcare costs (147,148).…”

Section: Health Economicsmentioning

confidence: 99%

Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology

Roberts

Xatzipsalti

Borrego

et al. 2013

Allergy

317

248

View full text Add to dashboard Cite

Rhinitis is a common problem in childhood and adolescence and impacts negatively on physical, social and psychological well-being. This position paper, prepared by the European Academy of Allergy and Clinical Immunology Taskforce on Rhinitis in Children, aims to provide evidence-based recommendations for the diagnosis and therapy of paediatric rhinitis. Rhinitis is characterized by at least two nasal symptoms: rhinorrhoea, blockage, sneezing or itching.

show abstract

Economic Evaluation of Specific Immunotherapy Versus Symptomatic Treatment of Allergic Rhinitis in Germany

Cited by 71 publications

References 37 publications

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology

Contact Info

Product

Resources

About